サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1726370

非アルコール性脂肪肝炎バイオマーカーの世界市場：市場規模・シェア・動向分析 (種類別・最終用途別・地域別)、セグメント別予測 (2025年～2030年)

Non-alcoholic Steatohepatitis Biomarkers Market Size, Share & Trends Analysis Report By Type (Serum Biomarkers, Hepatic Fibrosis Biomarkers), By End Use (Pharma & CRO Industry, Hospitals), By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 120 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.91円
非アルコール性脂肪肝炎バイオマーカーの世界市場：市場規模・シェア・動向分析 (種類別・最終用途別・地域別)、セグメント別予測 (2025年～2030年)
出版日: 2025年04月25日
発行: Grand View Research
ページ情報: 英文 120 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

非アルコール性脂肪肝炎バイオマーカー市場の成長と動向：

Grand View Research社の最新レポートによると、世界の非アルコール性脂肪肝炎バイオマーカー市場規模は2030年までに56億8,000万米ドルに達し、予測期間中にCAGR 23.3％で拡大すると予測されています。

肥満や糖尿病などの要因による非アルコール性脂肪性肝炎（NASH）の有病率の上昇が、NASHバイオマーカーの需要を大きく促進しています。非アルコール性脂肪性肝炎（NASH）の診断件数が増加していることが、正確な診断ツールの需要を後押ししています。さらに、啓発、早期発見、研究助成を促進する政府や医療の取り組みが、市場の成長をさらに加速させています。こうした取り組みは、NASHの負担増に対処し、バイオマーカー開発を通じて疾病管理を改善する上で極めて重要です。

診断技術の進歩と早期発見への関心の高まりがNASHバイオマーカー市場の成長を後押ししています。画像診断技術や血液ベースのバイオマーカーなどの革新的な非侵襲的検査法によって、より迅速で正確な診断が可能になります。早期発見により治療成績が向上するため、疾患の進行をモニタリングするための先進的なバイオマーカーに対する需要が高まっています。したがって、早期介入を重視する医療制度の高まりが市場の成長を促し、NASH管理のための改善されたソリューションの提供に役立っています。

NASHに対する認識の高まりは、効果的なバイオマーカーの需要を促進し、市場の大幅な成長につながると予想されます。この疾患に対する認識の高まりは、早期診断とより良い疾患管理を促します。この分野における研究開発の拡大は、新規バイオマーカーの発見を促進し、診断精度と治療戦略を向上させる。これらの要因がNASHバイオマーカーの需要を促進し、市場拡大に寄与すると予想されます。

非アルコール性脂肪肝炎バイオマーカー市場：分析概要

  • 種類別では、血清バイオマーカー分野が2024年に31.2%の最大収益シェアで市場をリード。
  • 肝線維症バイオマーカー分野は、肝障害の重症度と進行度を評価する上で重要な役割を果たすことから、予測期間中に最も速いCAGRで成長すると予測されています。
  • 最終用途別では、医薬品開発、臨床試験、バイオマーカー検証における重要な役割により、製薬・CRO業界が2024年に最大シェアを占めました。
  • 診断検査室セグメントは、認知度の向上と早期発見・診断需要の高まりにより、2025年から2030年にかけて最も急成長するセグメントとなります。
  • 北米は、高度な医療インフラ、肝疾患に対する高い認識、充実した研究投資により、2024年には約54％の最大シェアを占めました。

目次

第1章 分析方法・範囲

第2章 エグゼクティブサマリー

第3章 非アルコール性脂肪肝炎バイオマーカー市場：変動要因・傾向・範囲

  • 市場連関の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場促進要因の分析
    • 市場抑制要因の分析
  • 非アルコール性脂肪肝炎バイオマーカー市場：分析ツール
    • 業界分析：ポーターのファイブフォース分析
    • PESTEL分析

第4章 非アルコール性脂肪肝炎バイオマーカー市場：種類別の推定・動向分析

  • タイプセグメントダッシュボード
  • 非アルコール性脂肪肝炎バイオマーカー市場：変動分析、種類別
  • 世界の非アルコール性脂肪肝炎バイオマーカー市場：市場規模と動向分析、種類別（2018～2030年）
  • 血清バイオマーカー
  • 肝線維症バイオマーカー
  • アポトーシスバイオマーカー
  • 酸化ストレスバイオマーカー
  • その他

第5章 非アルコール性脂肪肝炎バイオマーカー市場：最終用途別の推定・動向分析

  • 最終用途セグメントダッシュボード
  • 非アルコール性脂肪肝炎バイオマーカー市場：変動分析、最終用途別
  • 世界の非アルコール性脂肪肝炎バイオマーカー市場：市場規模と動向分析、最終用途別（2018～2030年）
  • 製薬・CRO業界
  • 病院
  • 診断検査室
  • 学術研究機関

第6章 非アルコール性脂肪肝炎バイオマーカー市場：地域別の推定・動向分析

  • 市場ダッシュボード：地域別
  • 市場シェア分析：地域別（2024年・2030年）
  • 非アルコール性脂肪肝炎バイオマーカー市場：主なポイント
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • 韓国
    • オーストラリア
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東およびアフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 企業/競合の分類
  • ベンダー情勢
    • Key Company Heat Map Analysis, 2024
  • 企業プロファイル
    • GENFIT
    • Prometheus Laboratories
    • Siemens Healthineers AG
    • BioPredictive
    • Quest Diagnostics
    • AstraZeneca
    • Exalenz Bioscience Ltd（meridian bioscience）
    • Labcorp
    • Pfizer Inc.
    • Bristol-Myers Squibb Company
図表

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Non-alcoholic Steatohepatitis Biomarkers Market, by Region, 2018 - 2030 (USD Million)
  • Table 4 Global Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 5 Global Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 6 North America Non-alcoholic Steatohepatitis Biomarkers Market, by Country, 2018 - 2030 (USD Million)
  • Table 7 North America Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 8 North America Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 9 U.S. Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 10 U.S Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 11 Canada Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 12 Canada Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 13 Mexico Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 14 Mexico Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 15 Europe Non-alcoholic Steatohepatitis Biomarkers Market, by Country, 2018 - 2030 (USD Million)
  • Table 16 Europe Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 17 Europe Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 18 U.K. Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 19 U.K. Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 20 Germany Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 21 Germany Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 22 France Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 23 France Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 24 Italy Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 25 Italy Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 26 Spain Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 27 Spain Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 28 Denmark Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 29 Denmark Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 30 Sweden Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 31 Sweden Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 32 Norway Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 33 Norway Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific Non-alcoholic Steatohepatitis Biomarkers Market, by Country, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 36 Asia Pacific Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 37 Japan Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 38 Japan Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 39 China Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 40 China Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 41 India Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 42 India Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 43 South Korea Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 44 South Korea Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 45 Australia Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 46 Australia Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 47 Thailand Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 48 Thailand Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 49 Latin America Non-alcoholic Steatohepatitis Biomarkers Market, by Country, 2018 - 2030 (USD Million)
  • Table 50 Latin America Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 51 Latin America Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 52 Brazil Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 53 Brazil Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 54 Argentina Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 55 Argentina Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa Non-alcoholic Steatohepatitis Biomarkers Market, by Country, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 58 Middle East & Africa Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 59 South Africa Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 60 South Africa Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 62 Saudi Arabia Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 63 UAE Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 64 UAE Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 65 Kuwait Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 66 Kuwait Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Data Triangulation Techniques
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Primary Interviews
  • Fig. 5 Market Research Approaches
  • Fig. 6 Value-Chain-Based Sizing & Forecasting
  • Fig. 7 QFD Modeling for Market Share Assessment
  • Fig. 8 Market Formulation & Validation
  • Fig. 9 Non-alcoholic Steatohepatitis Biomarkers Market: Market Outlook
  • Fig. 10 Non-alcoholic Steatohepatitis Biomarkers Competitive Insights
  • Fig. 11 Parent Market Outlook
  • Fig. 12 Related/Ancillary Market Outlook
  • Fig. 13 Penetration and Growth Prospect Mapping
  • Fig. 14 Industry Value Chain Analysis
  • Fig. 15 Non-alcoholic Steatohepatitis Biomarkers Market Driver Impact
  • Fig. 16 Non-alcoholic Steatohepatitis Biomarkers Market Restraint Impact
  • Fig. 17 Non-alcoholic Steatohepatitis Biomarkers Market Strategic Initiatives Analysis
  • Fig. 18 Non-alcoholic Steatohepatitis Biomarkers Market: Type Movement Analysis
  • Fig. 19 Non-alcoholic Steatohepatitis Biomarkers Market: Type Outlook and Key Takeaways
  • Fig. 20 Serum Biomarkers Market Estimates and Forecast, 2018 - 2030
  • Fig. 21 Hepatic Fibrosis Biomarkers Market Estimates and Forecast, 2018 - 2030
  • Fig. 22 Apoptosis Biomarkers Market Estimates and Forecast, 2018 - 2030
  • Fig. 23 Oxidative Stress Biomarkers Market Estimates and Forecast, 2018 - 2030
  • Fig. 24 Others Market Estimates and Forecast, 2018 - 2030
  • Fig. 25 Non-alcoholic Steatohepatitis Biomarkers Market: End Use Movement Analysis
  • Fig. 26 Non-alcoholic Steatohepatitis Biomarkers Market: End Use Outlook and Key Takeaways
  • Fig. 27 Pharma & CRO Industry Market, 2018-2030 (USD Million)
  • Fig. 28 Hospitals Market, 2018-2030 (USD Million)
  • Fig. 29 Diagnostic Labs Market, 2018-2030 (USD Million)
  • Fig. 30 Academic Research Institutes Market, 2018-2030 (USD Million)
  • Fig. 31 Global Non-alcoholic Steatohepatitis Biomarkers Market: Regional Movement Analysis
  • Fig. 32 Global Non-alcoholic Steatohepatitis Biomarkers Market: Regional Outlook and Key Takeaways
  • Fig. 33 North America Market Estimates and Forecasts, 2018 - 2030
  • Fig. 34 U. S. Market Estimates and Forecasts, 2018 - 2030
  • Fig. 35 Canada Market Estimates and Forecasts, 2018 - 2030
  • Fig. 36 Mexico Market Estimates and Forecasts, 2018 - 2030
  • Fig. 37 Europe Market Estimates and Forecasts, 2018 - 2030
  • Fig. 38 U. K. Market Estimates and Forecasts, 2018 - 2030
  • Fig. 39 Germany Market Estimates and Forecasts, 2018 - 2030
  • Fig. 40 France Market Estimates and Forecasts, 2018 - 2030
  • Fig. 41 Italy Market Estimates and Forecasts, 2018 - 2030
  • Fig. 42 Spain Market Estimates and Forecasts, 2018 - 2030
  • Fig. 43 Denmark Market Estimates and Forecasts, 2018 - 2030
  • Fig. 44 Sweden Market Estimates and Forecasts, 2018 - 2030
  • Fig. 45 Norway Market Estimates and Forecasts, 2018 - 2030
  • Fig. 46 Asia Pacific Market Estimates and Forecasts, 2018 - 2030
  • Fig. 47 Japan Market Estimates and Forecasts, 2018 - 2030
  • Fig. 48 China Market Estimates and Forecasts, 2018 - 2030
  • Fig. 49 India Market Estimates and Forecasts, 2018 - 2030
  • Fig. 50 South Korea Market Estimates and Forecasts, 2018 - 2030
  • Fig. 51 Australia Market Estimates and Forecasts, 2018 - 2030
  • Fig. 52 Thailand Market Estimates and Forecasts, 2018 - 2030
  • Fig. 53 Latin America Market Estimates and Forecasts, 2018 - 2030
  • Fig. 54 Brazil Market Estimates and Forecasts, 2018 - 2030
  • Fig. 55 Argentina Market Estimates and Forecasts, 2018 - 2030
  • Fig. 56 Middle East & Africa Market Estimates and Forecasts, 2018 - 2030
  • Fig. 57 South Africa Market Estimates and Forecasts, 2018 - 2030
  • Fig. 58 Saudi Arabia Market Estimates and Forecasts, 2018 - 2030
  • Fig. 59 UAE Market Estimates and Forecasts, 2018 - 2030
  • Fig. 60 Kuwait Market Estimates and Forecasts, 2018 - 2030
目次
Product Code: GVR-1-68038-518-2

Non-alcoholic Steatohepatitis Biomarkers Market Growth & Trends:

The global non-alcoholic steatohepatitis biomarkers market size is anticipated to reach USD 5.68 billion by 2030 and expand at a CAGR of 23.3% during the forecast period, according to a new report by Grand View Research, Inc. The rising prevalence of Non-alcoholic Steatohepatitis (NASH), fueled by factors such as obesity and diabetes, is significantly driving the demand for NASH biomarkers. The growing diagnosis of NASH drives the demand for accurate diagnostic tools. In addition, government and healthcare initiatives promoting awareness, early detection, and research funding further accelerate market growth. These efforts are crucial in addressing the growing burden of NASH and improving disease management through biomarker development.

Advancements in diagnostic technologies and an increased focus on early detection drive the growth of the NASH biomarkers market. Innovative noninvasive testing methods such as imaging techniques and blood-based biomarkers enable quicker, more accurate diagnoses. Early detection improves treatment outcomes, fueling demand for advanced biomarkers to monitor disease progression. Hence, the growing emphasis of healthcare systems on early intervention impels market growth, helping provide improved solutions for NASH management.

Growing awareness of NASH is expected to propel the demand for effective biomarkers, leading to significant market growth. Increasing recognition of the disease encourages earlier diagnosis and better disease management. Expanding research and development in the field advances the discovery of novel biomarkers, improving diagnostic precision and treatment strategies. These factors are anticipated to drive the demand for NASH biomarkers, contributing to the market expansion.

Non-alcoholic Steatohepatitis Biomarkers Market Report Highlights:

  • On the basis of type, the serum biomarkers segment led the market with the largest revenue share of 31.2% in 2024, attributed to their ability to provide non-invasive, cost-effective, reliable diagnostic options.
  • The hepatic fibrosis biomarkers segment is projected to grow at the fastest CAGR during the forecast period, fueled by their crucial role in assessing the severity and progression of liver damage.
  • On the basis of end use, the pharma & CRO industry segment dominated the market with the largest share in 2024, driven by its critical role in drug development, clinical trials, and biomarker validation.
  • The diagnostic labs segment is set to be the fastest-growing segment from 2025 to 2030 due to increasing awareness and the rising demand for early detection and diagnosis.
  • North America accounted for the largest share of almost 54% in 2024, owing toits advanced healthcare infrastructure, high awareness of liver diseases, and substantial research investments.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. End Use
    • 1.2.3. Regional Scope
    • 1.2.4. Estimates and Forecasts Timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
    • 1.4.5. Details of Primary Research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type Outlook
    • 2.2.2. End Use Outlook
    • 2.2.3. Regional Outlook
  • 2.3. Competitive Scenario

Chapter 3. Non-alcoholic Steatohepatitis Biomarkers Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Non-alcoholic Steatohepatitis Biomarkers Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrant
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
      • 3.3.2.1. Political Landscape
      • 3.3.2.2. Technological Landscape
      • 3.3.2.3. Economic Landscape

Chapter 4. Non-alcoholic Steatohepatitis Biomarkers Market: Type Estimates & Trend Analysis

  • 4.1. Type Segment Dashboard
  • 4.2. Non-alcoholic Steatohepatitis Biomarkers Market: Type Movement Analysis
  • 4.3. Global Non-alcoholic Steatohepatitis Biomarkers Market Size & Trend Analysis, By Type, 2018 to 2030 (USD Million)
  • 4.4. Serum Biomarkers
    • 4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.5. Hepatic Fibrosis Biomarkers
    • 4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.6. Apoptosis Biomarkers
    • 4.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.7. Oxidative Stress Biomarkers
    • 4.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 5. Non-alcoholic Steatohepatitis Biomarkers Market: End Use Estimates & Trend Analysis

  • 5.1. End Use Segment Dashboard
  • 5.2. Non-alcoholic Steatohepatitis Biomarkers Market: End Use Movement Analysis
  • 5.3. Global Non-alcoholic Steatohepatitis Biomarkers Market Size & Trend Analysis, By End Use, 2018 to 2030 (USD Million)
  • 5.4. Pharma & CRO Industry
    • 5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.5. Hospitals
    • 5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.6. Diagnostic Labs
    • 5.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.7. Academic Research Institutes
    • 5.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 6. Non-alcoholic Steatohepatitis Biomarkers Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Dashboard
  • 6.2. Regional Market Share Analysis, 2024 & 2030
  • 6.3. Non-alcoholic Steatohepatitis Biomarkers Market by Region: Key Takeaways
  • 6.4. North America
    • 6.4.1. U.S.
      • 6.4.1.1. Key Country Dynamics
      • 6.4.1.2. Regulatory Framework/ Reimbursement Structure
      • 6.4.1.3. Competitive Scenario
      • 6.4.1.4. U.S. Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Canada
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Regulatory Framework/ Reimbursement Structure
      • 6.4.2.3. Competitive Scenario
      • 6.4.2.4. Canada Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Mexico
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Regulatory Framework/ Reimbursement Structure
      • 6.4.3.3. Competitive Scenario
      • 6.4.3.4. Mexico Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. U.K.
      • 6.5.1.1. Key Country Dynamics
      • 6.5.1.2. Regulatory Framework/ Reimbursement Structure
      • 6.5.1.3. Competitive Scenario
      • 6.5.1.4. U.K. Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.2. Germany
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Regulatory Framework/ Reimbursement Structure
      • 6.5.2.3. Competitive Scenario
      • 6.5.2.4. Germany Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.3. France
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Regulatory Framework/ Reimbursement Structure
      • 6.5.3.3. Competitive Scenario
      • 6.5.3.4. France Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.4. Italy
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Regulatory Framework/ Reimbursement Structure
      • 6.5.4.3. Competitive Scenario
      • 6.5.4.4. Italy Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.5. Spain
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Regulatory Framework/ Reimbursement Structure
      • 6.5.5.3. Competitive Scenario
      • 6.5.5.4. Spain Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.6. Denmark
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Regulatory Framework/ Reimbursement Structure
      • 6.5.6.3. Competitive Scenario
      • 6.5.6.4. Denmark Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.7. Sweden
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Regulatory Framework/ Reimbursement Structure
      • 6.5.7.3. Competitive Scenario
      • 6.5.7.4. Sweden Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.8. Norway
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Regulatory Framework/ Reimbursement Structure
      • 6.5.8.3. Competitive Scenario
      • 6.5.8.4. Norway Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Japan
      • 6.6.1.1. Key Country Dynamics
      • 6.6.1.2. Regulatory Framework/ Reimbursement Structure
      • 6.6.1.3. Competitive Scenario
      • 6.6.1.4. Japan Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.6.2. China
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Regulatory Framework/ Reimbursement Structure
      • 6.6.2.3. Competitive Scenario
      • 6.6.2.4. China Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.6.3. India
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Regulatory Framework/ Reimbursement Structure
      • 6.6.3.3. Competitive Scenario
      • 6.6.3.4. India Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.6.4. South Korea
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Regulatory Framework/ Reimbursement Structure
      • 6.6.4.3. Competitive Scenario
      • 6.6.4.4. South Korea Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Regulatory Framework/ Reimbursement Structure
      • 6.6.5.3. Competitive Scenario
      • 6.6.5.4. Australia Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.6.6. Thailand
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Regulatory Framework/ Reimbursement Structure
      • 6.6.6.3. Competitive Scenario
      • 6.6.6.4. Thailand Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Regulatory Framework/ Reimbursement Structure
      • 6.7.2.3. Competitive Scenario
      • 6.7.2.4. Brazil Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Regulatory Framework/ Reimbursement Structure
      • 6.7.3.3. Competitive Scenario
      • 6.7.3.4. Argentina Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Regulatory Framework/ Reimbursement Structure
      • 6.8.2.3. Competitive Scenario
      • 6.8.2.4. South Africa Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Regulatory Framework/ Reimbursement Structure
      • 6.8.3.3. Competitive Scenario
      • 6.8.3.4. Saudi Arabia Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Regulatory Framework/ Reimbursement Structure
      • 6.8.4.3. Competitive Scenario
      • 6.8.4.4. UAE Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Regulatory Framework/ Reimbursement Structure
      • 6.8.5.3. Competitive Scenario
      • 6.8.5.4. Kuwait Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/ Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. Key Company Heat Map Analysis, 2024
  • 7.4. Company Profiles
    • 7.4.1. GENFIT
      • 7.4.1.1. Company Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Strategic Initiatives
    • 7.4.2. Prometheus Laboratories
      • 7.4.2.1. Company Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Strategic Initiatives
    • 7.4.3. Siemens Healthineers AG
      • 7.4.3.1. Company Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Strategic Initiatives
    • 7.4.4. BioPredictive
      • 7.4.4.1. Company Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Strategic Initiatives
    • 7.4.5. Quest Diagnostics
      • 7.4.5.1. Company Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Strategic Initiatives
    • 7.4.6. AstraZeneca
      • 7.4.6.1. Company Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Strategic Initiatives
    • 7.4.7. Exalenz Bioscience Ltd (meridian bioscience)
      • 7.4.7.1. Company Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Strategic Initiatives
    • 7.4.8. Labcorp
      • 7.4.8.1. Company Overview
      • 7.4.8.2. Financial Performance
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Strategic Initiatives
    • 7.4.9. Pfizer Inc.
      • 7.4.9.1. Company Overview
      • 7.4.9.2. Financial Performance
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Strategic Initiatives
    • 7.4.10. Bristol-Myers Squibb Company
      • 7.4.10.1. Company Overview
      • 7.4.10.2. Financial Performance
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Strategic Initiatives